A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients with Non-Diabetic Chronic Kidney Disease
Trial to examine: -the impact of Finerenone vs. Placebo in delaying the progression of kidney disease. -the safety of Finerenone vs. Placebo in addition to standard of care treatment -quality of life measures via survey This trial will include 1580 participants worldwide. Study duration is approximately 2.5-4 years with an estimated 18 visits. Procedures include blood and urine collection, vital signs, EKG, questionnaires, and phone calls in between visits. The study offers an option for some visits to occur remotely. Compensation for participation is provided.More
-Age 18 years and older -Chronic kidney disease -Proteinuria -Non-diabetic Exclusion criteria: -Polycystic kidney disease -Organ transplant recipient -Uncontrolled blood pressure Further eligibility will be assessed by study coordinator.
Renal Research Center
Jessica Kendrick, MD
Protocol Number: 21-4551
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers